APPLICATION OF ORGANIC COMPOUNDS IN THERAPEUTIC PRACTICE FOR LIVER FUNCTION DISTURBANCES

• Published in: The Bulletin of Contemporary Clinical Medicine Vol. 15; no. 2; pp. 60 - 66
• Main Authors: SOROKINA, TATIANA V., DAVYDOVA, VALENTINA V., KOLESNIK, NATALIA Yu, BOLVANTSEVA, ALYONA I., SAMOYLOVA, YULIA G., OLEYNIK, OXANA A., TOLMACHEV, IVAN V.
• Format: Journal Article
• Language: English
• Published: 01.04.2022
• ISSN: 2071-0240; 2079-553X
• DOI: 10.20969/VSKM.2022.15(2).60-66

Introduction. The nonspecificity of the clinical manifestations of the initial stage of non-alcoholic fatty liver disease (NAFLD) - the stage of steatosis, is the reason for the untimely correction and progression of this disease. Aim. The aim of the study was to conduct a randomized open comparative study to determine the effectiveness of the use of the food supplement FanDetox as a source of organic compounds in liver function disorders. Material and methods. This study was a single-center randomized open one and included the study of the possibility of using the herbal product FanDetox in the complex therapy of NAFLD in patients aged 18 to 75 years with a verified diagnosis of obesity and the presence of signs of steatohepatosis, against the background of basic therapy with Carsil Forte. The study was conducted with the involvement of 68 people matched by sex and age, 34 of whom made up the main observation group, whose participants took the study product 1 sachet 2 times a day after meals, in the form of a suspension obtained after mixing the powder in 100 ml of water. The rest 34 patients made up the comparison group. Carsil Forte was chosen as a background drug for both groups. The duration of therapy for each study participant was 3 months. The follow-up process included patient visits with a detailed medical history, therapeutic examination, and laboratory and instrumental examinations. Statistical analysis was carried out using the IBM SPSS Statistics 23 program. Results and discussion. As a result, an improvement in the subjective well-being of patients, a decrease in the echoscopic manifestations of fatty hepatosis, a decrease in the longitudinal size of the liver, a decrease in the manifestations of the cytolysis syndrome and bilirubin levels, as well as a significant positive dynamics of the lipid spectrum in the blood of patients who received complex therapy, including the use of the FanDetox biologically active additive, compared with the comparison group undergoing therapy with the background drug Carsil Forte, were shown. Conclusion. It has been established that taking the food supplement FanDetox helps to reduce the manifestations of fatty hepatosis, reduce the longitudinal size of the liver, blood biochemistry indicators and the general well-being of patients.